Editorial Note: Originally published on July 1, 2026, this brief was updated on August 12, 2026, to incorporate the fiscal implications of the Centers for Medicare & Medicaid Services’ (CMS) recent recalculation of star ratings and its subsequent effect on 2027 Medicare Advantage (MA) quality bonus spending.
The Medicare Advantage (MA) program, which now serves 35 million Americans, stands at a critical fiscal crossroads. Central to its current structure is the Quality Bonus Program (QBP), an initiative born from the Affordable Care Act (ACA) designed to incentivize high-quality care through financial rewards. However, as the program’s costs balloon and questions regarding the validity of its "star rating" metrics persist, policymakers and independent watchdogs are increasingly calling for fundamental reform.
The Mechanics of the Quality Bonus Program
The QBP operates on a deceptively simple premise: Medicare Advantage plans that achieve a star rating of 4 or higher on a five-star scale receive increased federal payments. These additional funds are not required to be used for clinical improvements alone; rather, insurers may allocate them toward supplemental benefits, such as vision, hearing, and dental coverage, reduced cost-sharing, or the subsidization of Part D prescription drug premiums.
While the stated intent is to drive quality and provide consumers with clear benchmarks for plan selection, critics—including the Medicare Payment Advisory Commission (MedPAC)—argue the system is fundamentally flawed. Critics contend that the star ratings incorporate an overly broad range of measures, fail to adequately account for social risk factors, and suffer from a "level of aggregation" problem. Because ratings are assigned at the contract level rather than the plan level, a single contract may encompass multiple plans with vastly different networks and service populations, obscuring the actual quality of care provided to individual enrollees.
Chronology: A Decade of Explosive Spending
The financial trajectory of the QBP has been nothing short of dramatic. In 2015, the program cost taxpayers $3.0 billion. By 2026, that figure has more than quadrupled, reaching an estimated $13.4 billion.
- 2015–2018: The program gains momentum as MA enrollment begins to climb faster than initial projections.
- 2018: The Congressional Budget Office (CBO) estimates that eliminating the QBP would save federal taxpayers nearly $100 billion over a decade.
- 2023–2025: Enrollment surges to levels unforeseen by earlier models. The gap between traditional Medicare and MA spending widens, with the QBP contributing significantly to the fiscal disparity.
- 2026: CMS finalizes changes to the star rating system, removing administrative measures that failed to differentiate plan quality. Despite the intent to simplify, the policy is projected to increase federal spending by $18.6 billion over the next decade because more plans are expected to qualify for bonuses.
- 2027 Outlook: Following legal challenges from insurers like Clover Health, CMS is forced to recalculate ratings, resulting in an additional $600 million in unplanned spending for the 2027 fiscal year.
Supporting Data: Where the Money Goes
The 2026 data paints a stark picture of how bonus payments are distributed across the industry. Currently, 68% of all MA enrollees are in plans that qualify for bonus payments. However, the distribution is far from equitable among insurers and plan types.
Enrollment and Spending Variances
UnitedHealth Group, which commands 26% of the MA market, is set to receive 29% of all QBP spending in 2026, totaling roughly $3.9 billion. Conversely, Humana, the second-largest player with a 20% market share, will receive only 11% of the bonus pool. This drop-off is largely attributed to a significant decline in Humana’s star ratings for the 2025 plan year—a change that triggered a series of legal battles between the insurer and the federal government.
The Employer-Sponsored Premium
Employer- and union-sponsored plans occupy a unique space in the QBP landscape. While they account for only 16% of total MA enrollment, they represent 20% of QBP spending. Per-enrollee bonus payments for these group plans average $466, significantly higher than the $381 for individual plans and $318 for Special Needs Plans (SNPs). This creates a recurring question: Are these bonuses genuinely rewarding superior clinical outcomes, or are they simply subsidizing plans that already cater to more affluent or healthier populations?
Official Responses and Regulatory Friction
The relationship between CMS and the private insurance industry has become increasingly litigious. As star ratings determine not just bonuses, but also rebate percentages and eligibility for Special Enrollment Periods (SEPs), the stakes are high.
When CMS adjusts its "cut points"—the mathematical thresholds required to achieve a certain star rating—insurers are quick to challenge the methodologies. The recent legal pushback from Clover Health and Humana illustrates a broader trend: insurers are increasingly treating star rating methodology as a core business risk. CMS has consistently defended its right to update the scoring system to ensure it remains a valid indicator of quality, yet the agency’s recent appeals against court rulings suggest that the regulatory framework for these bonuses is currently in a state of flux.
Implications for the Future of Medicare
The fiscal pressure on the Medicare program is mounting, and the QBP is now seen by many as a primary driver of unsustainable spending. The following implications must be considered by policymakers:
1. The "Coding Intensity" Factor
The current analysis likely underestimates the true cost of the QBP. Because these estimates assume average health risk scores, they ignore "coding intensity"—the practice of documenting more medical diagnoses to increase risk-adjusted payments. MedPAC estimates that when accounting for these factors, the QBP could be costing the system billions more than the $13.4 billion headline figure.
2. Lack of Transparency
Data gaps remain a significant hurdle. The lack of granular information regarding the costs and benefits of employer-sponsored plans makes it nearly impossible to determine if the QBP is effectively serving the public interest or merely padding the margins of private insurers. Without better reporting, it is difficult to distinguish between plans that use bonuses to lower premiums and those that simply increase corporate profits.
3. The Impact of Administrative Simplification
While CMS’s decision to remove non-meaningful administrative measures is a step toward clarity, the unintended financial consequence—a $18.6 billion increase in spending—highlights the complexity of reform. Simply tweaking the metrics does not address the fundamental question: Should the federal government be providing billions in subsidies for plans that may not be delivering demonstrably superior care compared to traditional Medicare?
4. Potential for Systemic Reform
With the CBO’s 2018 projections now vastly eclipsed by actual enrollment numbers, the argument for reforming or eliminating the QBP has gained political traction. Proposals range from tying bonuses exclusively to clinical outcomes (rather than administrative processes) to capping total bonus spending as a percentage of overall MA outlays.
Conclusion
The Medicare Advantage Quality Bonus Program was intended to be a carrot, encouraging insurers to reach for the stars in terms of patient care. Today, however, it functions as a sprawling, costly, and often opaque mechanism that distributes billions of taxpayer dollars with questionable correlation to improved health outcomes. As the Medicare program faces long-term fiscal challenges, the QBP will undoubtedly remain a focal point of debate. Whether the program is pruned, overhauled, or fundamentally restructured will depend on the government’s ability to reconcile the private sector’s desire for predictable revenue with the public’s need for an efficient, high-quality, and solvent Medicare system.
For now, as long as 68% of enrollees are in "bonus-status" plans, the financial weight of this program will continue to exert a powerful influence on the future of the American healthcare landscape. The question remains: is the price of these stars worth the cost to the taxpayer?
About the Author
